CMS aiming for more transparency in drug pricing negotiations

The U.S. Centers for Medicare & Medicaid Services, or CMS, said it is considering ways to bring “greater transparency” to the Medicare drug pricing negotiation program mandated under the Inflation Reduction Act of 2022.

In a statement released Wednesday, CMS said